Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219277 · ClinicalTrials.gov registry record
Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening
A clinical trial of Breast Cancer, Liquid Biopsy, Early Detection, sponsored by Syantra.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 4
- Study locations
NCT07219277 is a study of Breast Cancer, Liquid Biopsy, Early Detection that is actively recruiting participants, run by Syantra. The registered enrollment target is 2,000 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT07219277, a study of Breast Cancer, Liquid Biopsy, Early Detection, is actively recruiting participants, sponsored by Syantra.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 4
- Study locations
Study Summary
Breast cancer is the most common cancer that spreads beyond the initial layer of tissue it developed in, and grows into surrounding healthy tissue in women worldwide. It is associated with significant illness and death. Identifying the disease in the early stage is important to achieving positive outcomes in response to diagnosis and treatment. The Syantra blood test has been developed over the past 10 years. This test involves examining blood samples to identify and analyze specific information. This information is run through a software program that then potentially identifies the presence of breast cancer in the blood sample. This test has the potential to increase early stage detection of breast cancer. The main goal of this study is to figure out how well the Syantra blood test identifies the presence of breast cancer in women 30-75 years of age. The study will also look at whether things like ethnicity, geography and certain individual characteristics (including breast density and elevated risk of breast cancer development) have an effect on how well the test works. This study will recruit women who are attending a visit at the site who are aged 30-75 who are undergoing testing for the presence of breast cancer as part of their regular screening or planned follow up imaging and/or biopsy. Participants who provide consent and meet eligibility criteria will complete a baseline questionnaire and have their blood drawn before any scheduled procedures. Relevant information will be collected from their medical record at the time of joining the study and will be reviewed and updated within 60 days and then again at 12 months following the baseline blood draw. Participants will not have to do anything after the initial visit where they may sign consent, complete the intake questionnaire and have their blood drawn.
Conditions Studied
Study Locations (4)
Arizona
- Vincere Cancer Center - Phoenix
New York
- Weill Cornell Medicine of Cornell University - New York
Alberta
- Alberta Cancer Research Biobank - Calgary
Other
- Manchester University NHS Foundation Trust - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-01-07 |
| Est. Completion | 2027-06-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07219277
The ClinicalTrials.gov registry entry for NCT07219277 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syantra, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer, Liquid Biopsy, Early Detection appearing as the primary indexed condition, and to 0 interventions.
NCT07219277 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, New York, Alberta.
Frequently Asked Questions
What is clinical trial NCT07219277 about?
NCT07219277 is a clinical study titled "Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening". Breast cancer is the most common cancer that spreads beyond the initial layer of tissue it developed in, and grows into surrounding healthy tissue in women worldwide. It is associated with significant illness and death. Identifying the disease in the early stage is important to achieving positive ou...
What is the current status of trial NCT07219277?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2026-01-07. Estimated completion is 2027-06-14.
What conditions does trial NCT07219277 study?
This clinical trial studies the following conditions: Breast Cancer, Liquid Biopsy, Early Detection.
Who is sponsoring clinical trial NCT07219277?
This trial is sponsored by Syantra, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219277 being conducted?
This trial has 4 study locations across Arizona, New York, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.